Supplementary Data — Sarilumab for COVID-19: real-time meta analysis of 11 studies

@CovidAnalysis, December 2025, Version 10V10
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ REMAP-CAP Gordon (RCT) 26% 0.74 [0.38-1.43] death 10/45 19/63 Improvement, RR [CI] Treatment Control REMAP-CAP Gordon (RCT) 50% 0.50 [0.21-0.85] death 45 (n) 397 (n) Lescure (DB RCT) 2% 0.98 [0.58-1.68] death 173 (n) 84 (n) Lescure (DB RCT) 3% 0.97 [0.46-2.07] death 18/173 9/84 Lescure (DB RCT) 0% 1.00 [0.47-2.14] death 17/159 9/84 Lescure (DB RCT) -5% 1.05 [0.57-1.91] ICU 114 (n) 56 (n) Lescure (DB RCT) -19% 1.19 [0.53-2.71] ICU 17/114 7/56 Lescure (DB RCT) 10% 0.90 [0.37-2.18] ICU 11/98 7/56 Lescure (DB RCT) 8% 0.92 [0.74-1.15] no improv. 173 (n) 84 (n) Lescure (DB RCT) 12% 0.88 [0.65-1.19] no improv. 173 (n) 84 (n) Lescure (DB RCT) 3% 0.97 [0.71-1.33] no improv. 159 (n) 84 (n) SARTRE Sancho-López (RCT) -3% 1.03 [0.14-7.46] death 2/99 2/102 SARTRE Sancho-López (RCT) 30% 0.70 [0.25-1.91] ICU 7/99 10/102 SARTRE Sancho-López (RCT) -14% 1.14 [0.65-2.00] no recov. 40/99 40/102 SARTRE Sancho-López (RCT) -3% 1.03 [0.48-2.20] no recov. 40/99 40/102 SARTRE Sancho-López (RCT) -3% 1.03 [0.48-2.20] no recov. 40/99 40/102 CORIMUNO-SARI-1 Mariette (RCT) 30% 0.70 [0.31-1.58] death 10/68 16/76 CORIMUNO-SARI-1 Mariette (RCT) 35% 0.65 [0.27-1.59] death 8/68 14/76 CORIMUNO-SARI-1 Mariette (RCT) 32% 0.68 [0.23-2.03] death 6/68 8/76 CORIMUNO-SARI-1 Mariette (RCT) -1% 1.01 [0.58-1.74] no recov. 18/68 20/76 CORIMUNO-SARI-1 Mariette (RCT) -10% 1.10 [0.69-1.74] progression 68 (n) 76 (n) CORIMUNO-SARI-2 Hermine (RCT) 26% 0.74 [0.35-1.58] death 14/48 13/33 SARICOR Merchante (RCT) -35% 1.35 [0.30-6.06] death 39 (n) 39 (n) SARICOR Merchante (RCT) 99% 0.01 [0.00-161] death 0/39 3/39 SARICOR Merchante (RCT) -41% 1.41 [0.31-6.31] death 4/37 3/39 SARICOR Merchante (RCT) -22% 1.22 [0.46-3.23] ventilation 39 (n) 39 (n) SARICOR Merchante (RCT) 22% 0.78 [0.17-3.48] ventilation 3/39 4/39 SARICOR Merchante (RCT) -68% 1.68 [0.47-5.98] ventilation 6/37 4/39 SARICOR Merchante (RCT) 36% 0.64 [0.31-1.32] progression 39 (n) 39 (n) SARICOR Merchante (RCT) 59% 0.41 [0.14-1.18] progression 5/39 11/39 SARICOR Merchante (RCT) 13% 0.87 [0.37-2.06] progression 10/37 11/39 SARCOVID García-Vic.. (RCT) -300% 4.00 [0.21-76.2] death 2/20 0/10 SARCOVID García-Vic.. (RCT) -450% 5.50 [0.31-97.2] ventilation 3/20 0/10 SARCOVID García-Vic.. (RCT) -33% 1.33 [0.73-2.45] 7-point status 20 (n) 10 (n) SARCOVID García-Vic.. (RCT) -50% 1.50 [0.68-3.31] 7-point status 20 (n) 10 (n) Branch-El.. (RCT) -350% 4.50 [1.01-20.1] death 6/20 2/30 Branch-El.. (RCT) -650% 7.50 [0.95-59.5] death/int. 5/20 1/30 Branch-El.. (RCT) -500% 6.00 [0.30-119] ventilation 2/20 0/30 Branch-El.. (RCT) -50% 1.50 [0.34-6.70] ICU 3/20 3/30 REGENERON P3 Sivapala.. (DB RCT) -8% 1.08 [0.83-1.39] death 567 (n) 286 (n) REGENERON P3 Sivapala.. (DB RCT) -17% 1.17 [0.54-2.56] death 21/137 9/70 REGENERON P3 Sivapala.. (DB RCT) 0% 1.00 [0.73-1.36] death 114/338 59/170 REGENERON P3 Sivapala.. (DB RCT) -32% 1.32 [0.74-2.36] death 40/92 16/46 REGENERON P3 Sivapala.. (DB RCT) 12% 0.88 [0.64-1.21] death 477 (n) 286 (n) REGENERON P3 Sivapala.. (DB RCT) 36% 0.64 [0.27-1.51] death 12/140 9/70 REGENERON P3 Sivapala.. (DB RCT) 19% 0.81 [0.57-1.14] death 70/242 59/170 REGENERON P3 Sivapala.. (DB RCT) -27% 1.27 [0.71-2.28] death 40/95 16/46 REGENERON P3 Sivapala.. (DB RCT) -6% 1.06 [0.91-1.23] no improv. 567 (n) 286 (n) REGENERON P3 Sivapala.. (DB RCT) -23% 1.23 [0.67-2.27] no improv. 29/137 12/70 REGENERON P3 Sivapala.. (DB RCT) -6% 1.06 [0.87-1.29] no improv. 164/338 78/170 REGENERON P3 Sivapala.. (DB RCT) -3% 1.03 [0.80-1.33] no improv. 62/92 30/46 REGENERON P3 Sivapala.. (DB RCT) 11% 0.89 [0.76-1.04] no improv. 477 (n) 286 (n) REGENERON P3 Sivapala.. (DB RCT) 0% 1.00 [0.53-1.88] no improv. 24/140 12/70 REGENERON P3 Sivapala.. (DB RCT) 16% 0.84 [0.68-1.03] no improv. 105/242 88/170 REGENERON P3 Sivapala.. (DB RCT) 5% 0.95 [0.73-1.24] no improv. 59/95 30/46 REGENERON P2 Sivapala.. (DB RCT) -7% 1.07 [0.44-2.59] death 180 (n) 90 (n) REGENERON P2 Sivapala.. (DB RCT) -1341% 14.41 [0.87-238] death 9/51 0/25 REGENERON P2 Sivapala.. (DB RCT) 30% 0.70 [0.37-1.35] death 23/88 15/44 REGENERON P2 Sivapala.. (DB RCT) -2% 1.02 [0.45-2.30] death 17/41 9/21 REGENERON P2 Sivapala.. (DB RCT) -22% 1.22 [0.76-1.97] death 187 (n) 90 (n) REGENERON P2 Sivapala.. (DB RCT) -300% 4.00 [0.20-80.3] death 2/50 0/25 REGENERON P2 Sivapala.. (DB RCT) -21% 1.21 [0.66-2.21] death 38/94 15/44 REGENERON P2 Sivapala.. (DB RCT) -15% 1.15 [0.52-2.53] death 20/43 9/21 REGENERON P2 Sivapala.. (DB RCT) -4% 1.04 [0.51-2.15] no improv. 180 (n) 90 (n) REGENERON P2 Sivapala.. (DB RCT) -292% 3.92 [0.98-15.7] no improv. 16/51 2/25 REGENERON P2 Sivapala.. (DB RCT) 40% 0.60 [0.43-0.84] no improv. 35/88 29/44 REGENERON P2 Sivapala.. (DB RCT) -7% 1.07 [0.66-1.75] no improv. 23/41 11/21 REGENERON P2 Sivapala.. (DB RCT) 12% 0.88 [0.69-1.12] no improv. 187 (n) 90 (n) REGENERON P2 Sivapala.. (DB RCT) 0% 1.00 [0.20-5.09] no improv. 4/50 2/25 REGENERON P2 Sivapala.. (DB RCT) 21% 0.79 [0.59-1.05] no improv. 49/94 29/44 REGENERON P2 Sivapala.. (DB RCT) -15% 1.15 [0.72-1.85] no improv. 26/43 11/21 ESCAPE Mastrorosa (RCT) -30% 1.30 [0.41-4.15] death 10/107 4/52 ESCAPE Mastrorosa (RCT) 7% 0.93 [0.67-1.25] no improv. 121 (n) 55 (n) ESCAPE Mastrorosa (RCT) -8% 1.08 [0.49-2.36] viral+ 17/79 7/35 Sarilumab COVID-19 outcomes c19early.org December 2025 Favors sarilumab Favors control
Fig. S1. All outcomes.